Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert(Institut Gustave Roussy), Victoria Atkinson(Greenslopes Private Hospital), Célèste Lebbé(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Francesco Cognetti(Apple (Israel)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Catalin Mihalcioiu(McGill University Health Centre), Catriona M. McNeil(Chris O’Brien Lifehouse), Cornelia Mauch(University Hospital Cologne), Lars Ny(Sahlgrenska University Hospital), Henrik Schmidt(Aarhus University Hospital), Jessica C. Hassel(German Cancer Research Center), Georgina V. Long(The University of Sydney), Micaela Hernberg(Apple (Israel)), Ewa Kalinka‐Warzocha(Apple (Israel)), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, Jesús Zoco, J. Charles(Apple (Israel)), Helen Gogas(National and Kapodistrian University of Athens), Anna Maria Di Giacomo(University of Siena), Benjamin Brady(Apple (Israel)), Ana Arance(Hospital Clínic de Barcelona), Sandra Re(Bristol-Myers Squibb (United States)), Kerry J. Savage(Spinal Cord Injury BC)
Cited by 226
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k